Juvenile Arthritis Quantitative Imaging

Launched by UNIVERSITY COLLEGE LONDON HOSPITALS · Feb 12, 2016

Keywords

ClinConnect Summary

This clinical trial, called "Juvenile Arthritis Quantitative Imaging," is studying how to better measure the activity of juvenile idiopathic arthritis (JIA) using a special type of imaging called magnetic resonance imaging (MRI). The goal is to create tools that can help doctors understand how active the disease is in young patients, specifically focusing on those with a type of JIA known as enthesitis-related arthritis (ERA).

To participate in the study, individuals must be between the ages of 12 and 24 and have a clinical diagnosis of JIA or, for control participants, mechanical back pain without signs of inflammation. Participants need to be comfortable with the MRI process, as it involves lying inside a machine that takes detailed pictures of the body. This study is currently looking for volunteers, and it's important to note that those with certain medical conditions or who cannot tolerate an MRI may not be eligible. If you or someone you know meets the criteria and is interested in contributing to this important research, you could help improve understanding and treatment options for juvenile arthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant is willing and able to give informed consent for participation in the study.
• • For cases, patients will have clinical diagnosis of JIA: enthesitis-related arthropathy, extended oligoarthritis or polyarthritis (defined according to ILAR criteria)
• • For controls, patients will have a diagnosis of mechanical back pain (though to arise from muscles, bones, ligaments or discs), with normal inflammatory markers
• • Age 12-24
• Exclusion Criteria:
• • Contra-indication to MRI scan (e.g. metal foreign object)
• • Unable to give consent
• • Unable to speak English
• • Unable to tolerate an MRI scan (e.g. due to claustrophobia, contrast allergy)
• • Renal or hepatic failure (eGFR \< 30ml/min for renal failure, where applicable)